Positron emission tomography imaging of the stability of Cu-64 labeled dipalmitoyl and distearoyl lipids in liposomes.
Changes in lipid acyl chain length can result in desorption of lipid from the liposomal anchorage and interaction with blood components. PET studies of the stability of such lipids have not been performed previously although such studies can map the pharmacokinetics of unstable lipids non-invasively in vivo. The purpose of this study was to characterize the in vivo clearance of (64)Cu-labeled distearoyl- and dipalmitoyl lipid included within long circulating liposomes. Distearoyl and dipalmitoyl maleimide lipids (1mol%) in liposomes were labeled with a (64)Cu-incorporated bifunctional chelator (TETA-PDP) after the activation of pyridine disulfide to thiol by TCEP. Long circulating liposomes containing HSPC:DSPE-PEG2k-OMe:cholesterol: x (55:5:39:1), where x was (64)Cu-DSPE or (64)Cu-DPPE, or HSPC:DSPE-PEG2k-OMe:cholesterol:(64)Cu-DSPE:DPPC (54:5:39:1:1) were evaluated in serum (in vitro) and via intravenous injection to FVB mice. The time-activity curves for the blood, liver, and kidney were measured from PET images and the biodistribution was performed at 48h. In vitro assays showed that (64)Cu-DPPE transferred from liposomes to serum with a 7.9h half-life but (64)Cu-DSPE remained associated with the liposomes. The half clearance of radioactivity from the blood pool was 18 and 5h for (64)Cu-DSPE- and (64)Cu-DPPE liposome-injected mice, respectively. The clearance of radioactivity from the liver and kidney was significantly greater following the injection of (64)Cu-DPPE-labeled liposomes than (64)Cu-DSPE-labeled liposomes at 6, 18 and 28h. Forty eight hours after injection, the whole body radioactivity was 57 and 17% ID/cc for (64)Cu-DSPE and (64)Cu-DPPE, respectively. These findings suggest that the acyl chain length of the radiolabel should be considered for liposomal PET studies and that PET is an effective tool for evaluating the stability of nanoformulations in vivo.
Department of Biomedical Engineering, University of California, Davis, CA 95616, USA. jwseo@ucdavis.edu
Jai Woong
JW
Seo
Shengping
S
Qin
Lisa M
LM
Mahakian
Katherine D
KD
Watson
Azadeh
A
Kheirolomoom
Katherine W
KW
Ferrara
D000818:Animals; D003301:Copper Radioisotopes / Q000737:chemistry / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D008081:Liposomes / Q000737:chemistry* / Q000493:pharmacokinetics*; D008301:Maleimides / Q000737:chemistry; D051379:Mice; D010714:Phosphatidylethanolamines / Q000737:chemistry* / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography
D003301:Copper Radioisotopes; D008081:Liposomes; D008301:Maleimides; D010714:Phosphatidylethanolamines; C038089:1,2-distearoylphosphatidylethanolamine; C043592:maleimide; C007510:1,2-dipalmitoyl-3-phosphatidylethanolamine
Clin Pharmacokinet. 2003;42(5):419-36
12739982
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jan-Feb;1(1):69-83
20049780
Nat Biotechnol. 2008 May;26(5):561-9
18438401
Int J Pharm. 2011 Jan 17;403(1-2):170-7
20934495
Biochemistry. 1991 Feb 12;30(6):1702-9
1993185
Ann Nucl Med. 2009 Feb;23(2):149-53
19225938
FEBS Lett. 1990 Jul 30;268(1):235-7
2384160
Expert Opin Drug Deliv. 2009 Dec;6(12):1297-309
19780711
J Control Release. 2008 Nov 12;131(3):160-6
18718854
J Control Release. 2010 Apr 2;143(1):13-22
20006659
J Nucl Med. 1981 Sep;22(9):810-4
7277025
Cancer. 1994 Feb 1;73(3 Suppl):779-86
8306260
Bioconjug Chem. 2008 Dec;19(12):2577-84
18991368
Bioconjug Chem. 2010 Jul 21;21(7):1206-15
20568726
Clin Cancer Res. 2001 Feb;7(2):223-5
11234871
Biochem J. 1991 Apr 1;275 ( Pt 1):139-44
2018469
Biochemistry. 1993 Dec 7;32(48):13318-26
8241188
Biochim Biophys Acta. 1994 Oct 12;1195(1):11-20
7918551
Adv Drug Deliv Rev. 1998 Jun 8;32(1-2):3-17
10837632
Nucl Med Biol. 2007 Feb;34(2):165-71
17307124
Lipids. 1982 Jun;17(6):448-52
7050582
Biochemistry. 1990 Feb 13;29(6):1593-600
2334718
Adv Drug Deliv Rev. 2004 Apr 29;56(8):1177-92
15094214
Mol Pharm. 2010 Feb 1;7(1):12-21
19621944
Acc Chem Res. 2009 Jul 21;42(7):881-92
19552457
Curr Pharm Des. 2004;10(24):2981-9
15379663
Int J Pharm. 2010 Jan 4;383(1-2):7-13
19729056
J Nucl Med. 1999 Jan;40(1):192-7
9935076
Nucl Med Biol. 1994 Jan;21(1):89-96
9234269
Pharm Res. 2010 Jul;27(7):1171-83
20333455
Nucl Med Biol. 1999 Apr;26(3):267-73
10363797
Biochim Biophys Acta. 2007 Jun;1768(6):1367-77
17400180
J Nucl Med. 1981 Jul;22(7):623-6
6788908
Biochim Biophys Acta. 2001 Aug 6;1513(2):193-206
11470091
Biomaterials. 2008 Apr;29(12):1976-88
18255141
Int J Rad Appl Instrum B. 1992 Nov;19(8):831-40
1428912
Biochemistry. 1993 Mar 30;32(12):3153-61
7681327
Nat Rev Drug Discov. 2005 Feb;4(2):145-60
15688077